Certara, Inc. (NASDAQ:CERT) Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC decreased its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 20.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 239,224 shares of the company's stock after selling 63,257 shares during the period. Granahan Investment Management LLC owned 0.15% of Certara worth $2,548,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Venturi Wealth Management LLC grew its position in Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the period. Johnson Financial Group Inc. purchased a new position in shares of Certara during the fourth quarter worth $47,000. Blue Trust Inc. lifted its position in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after purchasing an additional 822 shares during the period. Finally, ANTIPODES PARTNERS Ltd boosted its holdings in Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock valued at $58,000 after purchasing an additional 3,656 shares during the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Price Performance

Shares of Certara stock traded up $0.01 on Tuesday, reaching $12.14. The company's stock had a trading volume of 1,746,159 shares, compared to its average volume of 1,297,777. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.97 billion, a P/E ratio of -60.70, a PEG ratio of 9.29 and a beta of 1.57. The stock has a 50-day moving average price of $11.69 and a 200-day moving average price of $11.70. Certara, Inc. has a 52-week low of $8.64 and a 52-week high of $17.76.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. Analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CERT. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target for the company. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Robert W. Baird lifted their target price on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, KeyCorp boosted their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.